Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-28
2006-11-28
Mckenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C546S082000
Reexamination Certificate
active
07141567
ABSTRACT:
The invention relates to imidazopyridines of a certain formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion-inhibiting properties.
REFERENCES:
patent: 4468400 (1984-08-01), Gold et al.
patent: 4673679 (1987-06-01), Aungst et al.
patent: 5432183 (1995-07-01), Schulte
patent: 6160119 (2000-12-01), Senn-Bilfinger
patent: 6197783 (2001-03-01), Senn-Bilfinger et al.
patent: 6384048 (2002-05-01), Senn-Bilfinger
patent: 6436953 (2002-08-01), Senn-Bilfinger
patent: 6869949 (2005-03-01), Senn-Bilfinger et al.
patent: 6916825 (2005-07-01), Senn-Bilfinger et al.
patent: 4308095 (1994-09-01), None
patent: WO 95/27714 (1995-10-01), None
patent: WO 98/42707 (1998-10-01), None
patent: WO 98/54188 (1998-12-01), None
patent: WO 00/17200 (2000-03-01), None
patent: WO 00/26217 (2000-05-01), None
patent: WO 00/63211 (2000-10-01), None
patent: WO 01/72754 (2001-10-01), None
patent: WO 01/72755 (2001-10-01), None
patent: WO 01/72756 (2001-10-01), None
patent: WO 01/72757 (2001-10-01), None
Journal of Clinical Microbiology, “Detection of Helicobacter pulori in Gastric Mucosa of Patients with Gastroduodenal Diseases by PCR-Restriction Analysis Using RNA Polymerase Gene (rpoB)”, vol. 41, pp. 3387-3391.
International Journa of Pharmaceutics, “Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube”, vol. 299, pp. 65-72.
Senn-Bilfinger, J., et al., “Preparation of imidazonaphthyridines for prevention and treatment of gastrointestinal disease”. Chemical Abstracts, vol. 132, No. 11, Abstract No. 137385, 2000.
Kaminski, James J., et al., “Antiulcer Agents. 4. Conformational Considerations and the Antiulcer Activity of Substituted Imidazo 1,2-a pyridines and Related Analogues”. J. Med. Chem.: 32, 1686-1700, 1989.
Kaminski, James J., et al., “Antiulcer Agents. 5. Inhibition of Gastric H+/K+-ATPase by Substituted Imidazo [1,2-a] pyridines and Related Analogues and Its Implication in Modeling the High Affinity Potassium Ion Binding Site of the Gastric Proton Pump Enzyme”. J. Med. Chem.: 34, 533-541, 1991.
Kaminski, James J., et al., “Antiulcer Agents. 6. Analysis of the in Vitro Biochemical and in Vivo Gastric Antisecretory Activity of Substituted Imidazo 1,2-a pyridines and Related Analogues Using Comparative Molecular Field Analysis and Hypothetical Active Lattice Methodologies”. J. Med. Chem.: 40, 427-436, 1997.
Buhr Wilm
Kohl Bernhard
Senn-Bilfinger Jörg
Zimmermann Peter
Altana Pharma AG
Goldberg Joshua B.
McGee Sheldon M.
Mckenzie Thomas
Nath & Associates
LandOfFree
Polysubstituted imidazopyridines as gastric secretion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polysubstituted imidazopyridines as gastric secretion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polysubstituted imidazopyridines as gastric secretion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3625949